|
Market Closed -
Deutsche Boerse AG
02:02:05 2026-08-12 EDT
|
5-day change | 1st Jan Change | ||
| 4.400 EUR | -1.79% |
|
-0.56% | +120.00% |
| 07-09 | THX Pharma secures its financial roadmap |  |
| 06-23 | THX Pharma appoints Sophie Jacq Lapointe to its board of directors | |
| Market Cap | 60.43M 69.75M 56.62M 51.64M 97.09M 6.65B 98.58M 666M 260M 3.33B 262M 256M 11.11B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 36.73M 42.39M 34.41M 31.39M 59.01M 4.04B 59.92M 405M 158M 2.02B 159M 156M 6.75B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
91.97% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.79% | ||
| 1 week | -0.56% | ||
| Current month | +9.45% | ||
| 1 month | +26.80% | ||
| 3 months | +29.22% | ||
| 6 months | +13.99% | ||
| Current year | +120.00% |
| 1 week | 4.33 |  | 4.48 |
| 1 month | 3.6 | | 4.49 |
| Current year | 1.84 | | 4.49 |
| 1 year | 1.51 | | 4.49 |
| 3 years | 0.36 | | 4.49 |
| 5 years | 0.36 | | 9.15 |
| 10 years | 0.36 | | 21.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2022-12-31 | |
Christine Placet
DFI | Director of Finance/CFO | - | 2024-03-31 |
Marie Sebille
CTO | Chief Tech/Sci/R&D Officer | - | 2021-10-18 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 2024-03-30 | |
| Chairman | - | 2024-03-30 | |
Julien Veys
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.79% | -0.56% | - | - | 71.56M | |
| -0.73% | +7.82% | +73.81% | +102.34% | 70.51B | |
| +1.60% | +1.66% | +37.76% | +67.36% | 54.05B | |
| -0.22% | +33.59% | +8.43% | +489.75% | 28.95B | |
| +1.71% | +12.32% | +50.91% | +9.24% | 24.05B | |
| -0.06% | +0.61% | -16.45% | -13.26% | 23.31B | |
| -1.37% | +7.87% | +251.71% | +464.53% | 18.67B | |
| +2.21% | +7.66% | +47.18% | -20.09% | 18.37B | |
| +0.85% | +4.92% | +27.39% | +630.14% | 16.1B | |
| -1.85% | -11.15% | +32.75% | +134.11% | 12.72B | |
| Average | +0.03% | +8.58% | +57.06% | +207.12% | 29.64B | |
| Weighted average by Cap. | +0.28% | +9.58% | +55.31% | +169.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | 11.9M 13.73M 11.15M 10.17M 19.12M 1.31B 19.41M 131M 51.26M 656M 51.57M 50.45M 2.19B | 4.3M 4.96M 4.03M 3.67M 6.91M 473M 7.01M 47.39M 18.52M 237M 18.63M 18.23M 790M |
| Net Debt | -23.7M -27.35M -22.21M -20.25M -38.08M -2.61B -38.66M -261M -102M -1.31B -103M -100M -4.36B | -27.4M -31.63M -25.67M -23.42M -44.02M -3.02B -44.7M -302M -118M -1.51B -119M -116M -5.04B |
Employees
12
Calendar
| Date | Price | Change |
|---|---|---|
| 26-08-12 | €4.400 | -1.79% |
| 26-08-11 | €4.480 | -0.11% |
| 26-08-10 | €4.485 | +3.58% |
| 26-08-07 | €4.330 | -3.56% |
| 26-08-06 | €4.490 | +1.47% |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.380EUR
Average target price
5.800EUR
Spread / Average Target
+32.42%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ALTHX Stock
- 3VG Stock
Select your edition
All financial news and data tailored to specific country editions
